Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALPG | P10696 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30694356 | 0.87 | KDM4E (0.50) | PTPN1NPC1RAB9AKDM4ETDP1 | |
| SCHEMBL14013264 | 0.81 | PRSS1 (0.45) | PTPN1NPC1RAB9AKDM4ETDP1 | |
| SCHEMBL13831355 | 0.81 | RAB9A (0.39) | PTPN1NPC1RAB9AKDM4ETDP1 | |
| SCHEMBL310879 | 0.80 | NPC1 (0.60) | PTPN1NPC1RAB9AKDM4ETDP1 | |
| SCHEMBL1146715 | 0.80 | TSHR (0.60) | ALDH1A1SMN1; SMN2ALOX15CES1 | |
| SCHEMBL1094528 | 0.80 | NPC1 (0.64) | PTPN1NPC1RAB9AMEN1MAPT | |
| SCHEMBL11571 | 0.80 | NPC1 (0.64) | PTPN1NPC1RAB9AMEN1MAPT | |
| SCHEMBL743683 | 0.78 | TPMT (0.52) | PTPN1NPC1RAB9AACHEGSK3B | |
| SCHEMBL3112630 | 0.78 | GSK3B (0.61) | NPC1RAB9ATDP1ALDH1A1GAA | |
| SCHEMBL691537 | 0.78 | GSK3B (0.64) | PTPN1NPC1RAB9AKDM4EGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334867-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-11-23 | — | — | US | disclosed |
| US-20170166538-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2017-06-15 | — | — | US | disclosed |
| US-9428517-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2016-08-30 | — | — | US | disclosed |
| US-20160068539-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2016-03-10 | — | — | US | disclosed |
| US-9200006-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2015-12-01 | — | — | US | disclosed |
| US-20140221654-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2014-08-07 | — | — | US | disclosed |
| US-8735395-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2014-05-27 | — | — | US | disclosed |
| US-20130231349-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2013-09-05 | — | — | US | disclosed |
| US-8466158-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2013-06-18 | — | — | US | disclosed |
| US-8426421-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2013-04-23 | — | — | US | disclosed |
| US-20120289519-A1 | PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-20120220602-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2012-08-30 | — | — | US | disclosed |
| US-8242119-B2 | Protease inhibitors | MEDIVIR AB (SE) | 2012-08-14 | — | — | US | disclosed |
| US-8198283-B2 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2012-06-12 | — | — | US | disclosed |
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2011-05-05 | — | — | US | disclosed |
| US-20110039862-A1 | Protease Inhibitors | MEDIVIR AB (SE) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289519-A1 | PROTEASE INHIBITORS | F2RL1, F2RL3, PREP | PTPN1 3495/4885NPC1 1931/4885RAB9A 2331/4885 |
| US-20110105524-A1 | CYSTEINE PROTEASE INHIBITORS | CTSK, CTSL, CTSV | PTPN1 3272/4885NPC1 3347/4885RAB9A 806/4885 |
| US-20160068539-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | PTPN1 3792/4885NPC1 303/4885RAB9A 1811/4885 |
| US-20170334867-A1 | PROTEASE INHIBITORS | CTSK, MMP26, MMP3 | PTPN1 4204/4885NPC1 463/4885RAB9A 1940/4885 |
| US-20110039862-A1 | Protease Inhibitors | CTSK, CTSF, CTSS | PTPN1 3780/4885NPC1 300/4885RAB9A 1774/4885 |
| US-20170166538-A1 | PROTEASE INHIBITORS | MMP8, CTSK, CTSS | PTPN1 3714/4885NPC1 260/4885RAB9A 1077/4885 |
| US-20120220602-A1 | CYSTEINE PROTEASE INHIBITORS | CTSK, CTSL, CTSV | PTPN1 3272/4885NPC1 3347/4885RAB9A 806/4885 |
| US-20130231349-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | PTPN1 3780/4885NPC1 300/4885RAB9A 1774/4885 |
| US-20140221654-A1 | PROTEASE INHIBITORS | CTSK, CTSF, CTSS | PTPN1 3792/4885NPC1 303/4885RAB9A 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.